Iambic Therapeutics
San Diego AI-native drug discovery company whose Enchant platform took a cancer drug to the clinic in about two years.
Overview
Iambic Therapeutics is a San Diego AI-native drug-discovery company (formerly Entos) building the Enchant platform, a multimodal model that makes high-confidence predictions even in data-poor, early- and clinical-stage settings. In 2025 it released Enchant v2 and reported that its lead asset IAM1363, for HER2-driven cancers, showed anti-tumour activity in heavily pretreated patients — reaching the clinic in about two years, roughly a third of the usual time. Iambic was named to CNBC's Disruptor 50 list in both 2025 and 2026.
Pricing
Pricing shown for reference only. These figures reflect RECATOOLS research as of 24 Jul 2026 and may be out of date or incomplete. This is not financial or purchasing advice — always confirm the current price on the provider’s official website before making any decision.
ASEAN Perspective
Iambic Therapeutics in Southeast Asia
ASEAN-region availability and pricing notes coming soon. Drop the editorial team a note via /contact/ if you can supply local context (Singapore/Malaysia/Indonesia/Thailand/Vietnam).
What this is for: AI-native drug discovery and development, using the Enchant platform to predict molecule properties and speed candidates to the clinic.
Who this is for: Pharma and biotech partners, plus the company's own oncology pipeline.
Availability: Enterprise partnerships and an internal drug pipeline — not a consumer or self-serve tool.
What people say
Iambic Therapeutics' reception is that of a well-regarded private techbio rather than a reviewed product — there is no G2 or app-store signal, and the audience is pharma partners and its own pipeline. The strongest external validation is being named to CNBC's Disruptor 50 list in both 2025 and 2026 (repeat status shared with the likes of OpenAI and SpaceX). Its headline scientific claim drew attention. The lead asset, IAM1363, a selective Type-II HER2 inhibitor, reached the clinic in about two years — roughly a third of the usual timeline — and Phase 1/1b data presented at ESMO 2025 showed monotherapy anti-tumour activity in heavily pretreated HER2-altered patients.
This is, however, very early clinical evidence. Anti-tumour activity in a small, heavily pretreated Phase 1 population is encouraging but far from proof of efficacy, and, as with every AI-native drug-discovery company, the platform's ultimate test — an approved medicine — has not yet been met. Speed-to-clinic, after all, is a process metric, not a clinical outcome.
Coverage to date is largely company announcements and industry press with little independent critical scrutiny, so enthusiasm should be read accordingly. Iambic is a promising AI-first oncology story with a molecule in patients, but it's still awaiting the later-stage data that would confirm its platform's advantage.
Summary of public user & expert reviews, compiled by RECATOOLS.
About this listing
This entry was compiled from publicly available data including Iambic Therapeutics's official website, press releases, documentation, and reputable third-party publications. RECATOOLS is not affiliated with Iambic Therapeutics unless explicitly stated.
Third-party AI tools update their pricing, features, availability, and policies frequently. Information here may be outdated by the time you read this — we make reasonable efforts to keep listings current, but cannot guarantee absolute accuracy.
For the latest details, please refer to Iambic Therapeutics directly →
Spotted something out of date? Suggest an update →
More in Research & Data
